The PALOMA-2 trial confirmed that the combination of palbociclib and letrozole leads to significantly longer progression-free survival than letrozole alone in postmenopausal women with advanced breast cancer, i.e., HR+ and HER2-. This evidence concerns the gene ERBB2 and breast cancer.